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T
he arguments made by Dr O’Reilly are largely smoke and
mirrors, with facts taken out of context to buttress his
position. We are told that studies of CTOs have exceeded
4000 subjects, but Dr O’Reilly does not mention that only 416
subjects have completed RCTs. Dr O’Reilly also fails to men-
tion that the benefits of CTOs largely disappear when people
are compared with randomly or appropriately matched con-
trol subjects. This finding includes preliminary results from
Ontario comparing patients on ACT and CTOs with patients
on ACT alone—results showing no additional benefit from
CTOs (1). Regarding the assertion that CTOs improve com-
pliance with follow-up, our initial argument also dealt with
the fallacy of relying on outpatient contacts to evaluate CTOs.
The NNT is useful in summarizing the effects of RCTs.
Depending on how the NNT is calculated, it would take up to
100 CTOs to avoid a single admission and 500 to avoid an
arrest, although these figures are lower, but still unacceptable,
with intention-to-treat analyses (2).
Dr O’Reilly also chides us for overreliance on RCTs. On the
contrary, we endorse the use of interrupted time series and
controlled before-and-after designs that meet the Cochrane
Collaboration’s criteria for inclusion in their increasing num-
ber of reviews that extend beyond RCTs. We would hardly
dismiss a methodology that has formed the basis of our own
quasi-experimental studies (3,4). However, any study design
has to meet minimum criteria, and when we tried to extend our
original Cochrane Review (2) to other designs, we could only
include another 3 studies—and even with 1108 subjects,
results remained inconclusive (5).
Clinical experience, as well as research evidence, informs our
skepticism about CTOs. We are skeptics but not opponents of
CTOs—our view would change were appropriate evidence to
appear. One of us worked for several years in Western
Australia, where CTOs were introduced in 1998, and
observed that compulsory treatment does not translate well
into the community. The level of clinical observation and
supervision can never reach the level that is possible with
inpatients. Patients with florid psychosis simply refused any
treatment and still had to be admitted compulsorily when they
became too ill. Those with encapsulated delusions simply
bided their time, finished their order, and then openly refused
the medication that we were never sure they had been taking in
the first place. Dr O’Reilly’s more positive experiences may
be influenced by the requirement for patients or substitute
decision makers in Ontario to consent to a CTO—a sort of
advance directive with attitude. Such cases will always have a
better prognosis, which cannot be said of patients who refuse
to comply with any intervention in the community. In current
practice in Halifax’s North End, a socially deprived area
where patients often have multiple comorbidities, limited
insight, and few social supports, CTOs would do little to help.
Here are the key questions:
 Would any other intervention be introduced with so little
evidence? Proponents may mix and match designs to fit
their opinions, but the fact remains that CTOs do not
produce the desired results when recipients are compared
with randomly or appropriately matched control subjects.
 Why is this measure so popular with legislators? It is
popular because passing legislation is easier than
addressing inadequate funding for psychiatric services.
 Why are families so keen on this measure? They like it
because, given current funding levels, they are desperate
for anything that promises assistance, however illusory. If
you are drowning, you will gladly climb aboard a
lifeboat, however leaky—but this enthusiasm is not
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Abbreviations used in this article
CTO community treatment order
ACT assertive community treatment
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shared by patients. One has likened CTOs to “house
arrest in home-based institutions.”
 Why are clinicians joining the CTO bandwagon and
letting politicians off the hook when we should be uniting
with families and patients to achieve decent funding
levels for psychiatric services? Ask them, not us.
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